A Multinational, Multicenter, Randomized, Double Blind Study to Evaluate the Efficacy, Pharmacokinetics, Pharmacodynamics, Safety, Tolerability, and Immunogenicity of TEV-45779 Compared to Omalizumab (XOLAIR) in Patients With Chronic Idiopathic Urticaria/Chronic Spontaneous Urticaria Who Remain Symptomatic Despite Antihistamine (H1) Treatment
Latest Information Update: 17 Jun 2024
At a glance
- Drugs Omalizumab (Primary)
- Indications Chronic urticaria
- Focus Registrational; Therapeutic Use
- Sponsors Teva Pharmaceuticals USA
- 18 Apr 2024 Status changed from active, no longer recruiting to completed.
- 21 Mar 2024 Planned End Date changed from 1 Jun 2024 to 5 Apr 2024.
- 21 Jun 2023 Planned End Date changed from 1 May 2024 to 1 Jun 2024.